ABSTRACT: Vitamin D has been recognized for more than a century as essential for the normal development and mineralization of a healthy skeleton. More extensive roles for vitamin D were suggested by the discovery of the vitamin D receptor (VDR) in tissues that are not involved in calcium and phosphate metabolism. VDR has been discovered in most tissues and cells in the body and is able to elicit a wide variety of biologic responses. These observations have been the impetus for a reevaluation of the physiologic and pharmacologic actions of vitamin D. Here, we review the role of vitamin D in regulation of the immune system and its possible role in the prevention and treatment of cancer and immune-mediated diseases.
Vitamin D Overview
Most humans depend on sun exposure to satisfy their requirements for vitamin D. Brief exposure to direct sunlight on a bright summer day is all the body needs to produce sufficient cholecalciferol (or vitamin D 3 ). 1 Skin exposure to ultraviolet B light (wavelength 290 -315 nm) initiates the photochemical conversion of 7-dehydrocholesterol to previtamin D 3 in the epidermis and dermis. Body heat then catalyzes the rapid isomerization of previtamin D 3 to vitamin D 3 (cholecalciferol), which binds to the vitamin-D-binding protein (VDBP) in the extracellular space.
2 Vitamin D 3 is transported to the liver, which uses 25-hydroxylase to produce 25-hydroxyvitamin D 3 , or 25(OH)D 3 .
Although endogenous production of vitamin D typically provides most of the vitamin D requirement, vitamin D can be ingested orally as either vitamin D 3 (cholecalciferol) or D 2 (ergocalciferol, derived from the irradiation of plant sterols). Very few foods naturally contain vitamin D: oily fish and fish products such as cod-liver oil, salmon, mackerel, and herring contain approximately 300 -500 international units (IU) of vitamin D per serving. 3 Foods in the United States that are fortified with vitamin D include milk, orange juice, and some cereals, breads, yogurts, and cheeses. Most European countries permit margarine and some cereals to be fortified with vitamin D, and a few countries, including Sweden, also permit milk to be fortified with this vitamin.
25-Hydroxyvitamin D [25(OH)D]
derived from endogenous production or exogenous sources is the major vitamin D metabolite in the human body's circulation system and is the best known indicator of vitamin D status. There is debate regarding cutoffs for vitamin D deficiency and insufficiency using 25(OH)D concentrations. The current thinking is that the traditional cutoff for deficiency, 10 ng/mL of 25(OH)D (above which protection from rickets or osteomalacia is conferred), is too low to indicate vitamin D adequacy. A low serum 25(OH)D concentration, often referred to as hypovitaminosis D, is not simply a biochemical abnormality. It is associated with physiologic, pathologic, and clinical evidence of vitamin D deficiency, including increased parathyroid hormone secretion, increased bone turnover, osteoporosis and mild osteomalacia, and an increased risk of hip and other fractures. To prevent more subtle or long-term effects of vitamin D insufficiency, circulating concentrations of at least 30 ng/mL 25(OH)D may be warranted. 3 In the kidney, 25(OH)D is further hydroxylated to 1␣,25-dihydroxyvitamin D [1␣,25(OH) 2 D 3 , calcitriol], the most biologically active form of the vitamin, by renal 1␣-hydroxylase under the control of parathyroid hormone. 1␣,25(OH) 2 D 3 principally targets the intestine, kidney, and bone to regulate calcium and phosphate homeostasis. Calcitriol is a lipid-soluble hormone that interacts with its vitamin D receptor (VDR) in the small intestine to increase the expression of an epithelial calcium channel, calcium-binding protein, and a variety of other proteins to help in transport of calcium from the intestinal lumen into circulation. Calcitriol also interacts with its VDR in the osteoblasts, which results in an increase in the mobilization of osteoclast precursors to become mature osteoclasts. The end result is mobilization of calcium stores from the skeleton to maintain calcium homeostasis. [1] [2] [3] [4] [5] [6] These well-defined, calcemic functions of vitamin D are illustrated in Figure 1 . It should be noted that 1␣,25(OH) 2 D 3 circulates at concentrations 1000-fold less than that of 25(OH)D, and that its half-life is hours rather than weeks, as is the case for 25(OH)D.
More recently, VDRs were found in cells of tissues not involved in calcium homeostasis, and extrarenal tissues were found to produce 1␣,25(OH) 2 D 3 . These pathways are also indicated in Figure 1 and supported the hypothesis that vitamin D plays additional roles in cellular differentiation and the control of proliferation in a variety of cell types. These results have bolstered at a biochemical level what epidemiologists have been witnessing in observational studies: that vitamin D status may protect against certain cancers, as well as some autoimmune conditions.
Vitamin D and Cancer Prevention

Epidemiologic Studies
Geography, sunlight, and cancer risk. Most of the information about vitamin D and cancer prevention has been based on observational, case-control, or cohort studies linking sunlight exposure to cancer incidence or survival. The first of these studies was documented nearly a half century ago, when it was reported that individuals living in the northeast regions of the United States had an approximately 2-fold higher risk of dying of cancer than those living in southern regions. 7 Recently, several more studies found a similar association between latitude and the risk of developing prostate, breast, and colon cancer in the United States and Europe. 8 -10 Colon cancer mortality was subsequently found to be higher among people from the Northeastern United States compared with people living in southern states. 11 It is now well established that the risk of developing and dying of prostate, breast, colon, ovarian, esophageal, non-Hodgkin's lymphoma, and a number of other lethal cancers correlated with living at higher latitudes. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Several investigators have confirmed the reciprocal relationship of sunlight exposure and cancer. Most recently, Grant 24, 25 reported that increased sun exposure decreases mortality from common cancers in both white men and women. 7 Grant 17 suggested that 25% of breast cancer mortality in Europe was related to living at a higher latitude and being vitamin D deficient.
These observations are also supported by a report of men who had little sun exposure and developed prostate cancer 3-5 years earlier than men who had optimal sun exposure. 26 Vitamin D deficiency was reported to increase the risk for prostate cancer, and sunlight exposure is inversely proportional to prostate cancer mortality. Colon cancer incidence was evaluated in California because the state has a wide range of latitudes. Living in San Diego was reported to significantly decrease the risk of developing colon cancer compared with living in San Francisco or further north. 27 There has been speculation that subjects living further north synthesized less vitamin D and that therefore vitamin D seems to be protective against Studies have looked more specifically at quantitative estimates of sunlight exposure and cancer risk or mortality. Men with elevated levels of sunlight exposure had a later onset of prostate cancer than those with low levels of sunlight exposure. 18 Solar ultraviolet (UV)-B exposure was inversely related to the risk of dying of cancer in men and women in the United States. 28 Putative mechanisms for vitamin D protection against cancer. The original hypothesis for why exposure to sunlight decreased the risk of common cancers was that increased production of vitamin D 3 in the skin resulted in higher circulating levels of 25(OH)D 3 , which could be metabolized by the kidneys to 1␣,25(OH) 2 D 3 . The discovery that VDRs existed in tissues that were not involved in calcium metabolism (ie, prostate, breast) reinforced the possibility that enhanced production of renal 1␣,25(OH) 2 D 3 could influence noncalcemic tissues. Studies demonstrated that 1␣,25(OH) 2 D 3 markedly inhibited a variety of genes responsible for cellular proliferation, including p21 and p27, and was also responsible for enhancing apoptotic activities and a variety of genes that regulate cellular differentiation. 29 However, because the kidney's production of 1␣,25(OH) 2 D 3 is exquisitely regulated, it could not serve as the source of the active 1␣,25(OH) 2 D 3 responsible for the newly recognized cellular functions. Thus, another hypothesis to explain the observations that sunlight provided a protective effect via vitamin D was needed. [1] [2] [3] [4] Another possibility was that the "target" cells of interest were themselves converting 25(OH)D to 1␣,25(OH) 2 D 3 . Along these lines, cultured keratinocytes and prostate cells obtained from nondiseased prostate biopsies converted 25(OH)D to 1␣,25(OH) 2 D 3 18,27,30 ( Figure 2 ). Following these observations, it has been noted that the colon, lung, breast, and other tissues all express the 25(OH)D-1␣-hydroxylase (1-OHase; cyp 27 B1). 31 Thus, it has been suggested that raising blood levels of 25(OH)D provides an adequate substrate for the prostate, colon, and breast to produce their own local 1␣,25(OH) 2 D 3 , which, in turn, is capable of regulating a variety of cellular processes that help control cellular growth and prevent malignancy.
Animal models. Although the epidemiologic evidence linking sun exposure to cancer risk seems strong, whether vitamin D deficiency per se promotes tumor growth remained unclear. To this end, a study evaluated the growth of a mouse colon cancer cell line MC-26 in Balb/c mice that were either vitamin D deficient or vitamin D sufficient. 32 The tumors grew much more rapidly in the vitamin D-deficient mice. By the end of the study on day 19, tumors in the vitamin D-deficient mice were on (Table 1) . 20, [35] [36] [37] [38] 41 Three case-controlled studies demonstrated no association between dietary vitamin D intake and breast cancer risk 35, 39, 40 ; however, small sample size and selection bias may have skewed the results. On the other hand, the Nurses Health Study demonstrated an inverse association between vitamin D intake and breast cancer risk among premenopausal women but no association among postmenopausal women. 41 Along these lines, the Cancer Prevention Study II Nutrition Cohort found no correlation between dietary intake of vitamin D and development of breast cancer in postmenopausal women, 38 and 2 additional studies determined that the dietary intake of vitamin D in the female adolescent had no bearing in determining future breast cancer risk. 36, 37 However, researchers provided additional preliminary evidence demonstrating a potential role of vitamin D in decreasing breast cancer risk. In a population-based, case-controlled study in Ontario, women with breast cancer (identified through the Ontario Cancer Registry) and controls were interviewed about their past and present diets and sun exposure.
The investigators' preliminary analysis suggests that earlier exposures to vitamin D during breast development in adolescence may be more significant for reducing breast cancer risk than recent exposures. 42, 43 A recent study seeking to estimate the amount of vitamin D required to reduce the inci- The results demonstrated that women who consumed 1000 IU a day of vitamin D in addition to the normal background amount had a 10% reduced risk of breast cancer. 43 Garland and colleagues 44 plotted a dose-response gradient and found that as quintiles of serum 25(OH)D (0 -11 ng/mL, 12-25 ng/mL, 26 -31 ng/mL, 32-42 ng/mL, and Ͼ42 ng/mL) increased, the risk of breast cancer significantly decreased. A serum 25(OH)D concentration exceeding 52 ng/mL (which would require intake of Ͼ2700 IU/d of vitamin D 3 in an individual weighing 70 kg) was associated with 50% lower risk of breast cancer compared with a serum concentration of Ͻ12 ng/mL. The authors noted that the US median intake of 320 IU/d of vitamin D is only about one-tenth of the amount found to be associated with a 50% reduction of breast cancer incidence. They concluded that increasing daily intake of vitamin D, perhaps by fortification of foods, should be considered. Studies analyzing endogenous circulating vitamin D levels and breast cancer risk are shown in Table 2 . 12, 19, 34, 45, 46 A recent study by Dr Walter Willett's group from Harvard University found that higher serum vitamin D levels correlated with reduced risk for certain forms of cancers in a population of middle-aged to elderly men in a retrospective analysis of data from a major study of health professionals. 48 Giovannucci and colleagues 48 analyzed prospective data from Harvard's Health Professionals Follow-up Study, which includes Ͼ50,000 men aged 40 -75 years. Higher serum levels of vitamin D were associated with a significantly lower incidence of colorectal, pancreatic, esophageal, and oral/pharyngeal cancers. An increase of 25 nmol/L in serum vitamin D level was associated with a 17% decline in overall cancer incidence and a 29% drop in total cancer deaths. For cancers involving the digestive system, a 25 nmol/L increase in vitamin D reduced cancer incidence by 43% and mortality by 45%. This study was the first to examine total cancer incidence and mortality by using a comprehensive assessment of factors that determine 25(OH)D levels. The authors estimated that cancer mortality for US men could be reduced by 29% if serum vitamin D levels were increased by 25 nmol/L throughout the male population. The findings from this cohort study are the latest of several 49 -52 A recent editorial also noted that "the amount of sun needed to produce adequate levels of vitamin D, at least for bone health, is modest and can be obtained in a light-skinned person by a brief summertime afternoon stroll." 53 Other previous reports support a role for vitamin D in the prevention of colorectal cancer. 15 56 reported that vitamin D also serves a protective role against the development of non-Hodgkin's lymphoma. Vitamin D (chiefly contained in fish) provided protection against nonHodgkin's lymphoma that was stronger in women, whereas no differences emerged according to age (odds ratio [OR] ϭ 0.4; 95% confidence interval [CI], 0.2-0.9). Vitamin D also seems to play a protective role in pancreatic cancer. 57 In 2 US cohorts, increased intakes of vitamin D were associated with reduced risks for pancreatic cancer, suggesting a potential role for vitamin D in the pathogenesis and prevention of this malignancy.
Melanoma, on the other hand, has been linked to sun exposure. Thus, the risk of excessive sun exposure needs to be weighed against the benefit of sun-derived vitamin D. Li et al 58 reported that genetic variants (ie, TaqI t protective allele and FokI f risk allele) in VDR may alter risk of cutaneous melanoma. Thus, genetic alternations in VDRs may in part determine the risk for developing cutaneous melanoma from sun exposure.
Mechanisms Involved in the Anticancer Effects of Vitamin D
Over the past quarter century, evidence for the anticancer properties of vitamin D and its analogs has been emerging in the literature. The volume of data supports a multipronged attack that involves growth arrest at the G1 phase of the cell cycle, apoptosis, tumor-cell differentiation, disruption of growth-factor-mediated cell survival signals, and inhibition of angiogenesis and cell adhesion ( Figure  2 ). Processes involved in the tumor suppressive activity of vitamin D analogues include inhibition of cell proliferation, induction of apoptosis, inhibition of cell adhesion, G 1 -phase cell-cycle arrest, promotion of cell differentiation, inhibition of angiogenesis, alteration of growth factors, and inhibition of metastasis. 59, 60 Thus, VDR-mediated pathways constitute potential therapeutic targets for cancer prevention and treatment.
Proposed Cellular Mechanisms
Cell cycle regulators. Direct regulation of the cell cycle by 1␣,25(OH) 2 D 3 has been studied predominantly in in vitro systems. The 1␣,25(OH) 2 D 3 -VDR system arrests the cancerous cell cycle at the G 0 -G 1 transition through multiple mechanisms. 59 In the monomyelocytic cell line U937, 1␣,25(OH) 2 2 D 3 increases the expression of p27 as well as p15, p16, and p18, which effectively inhibits the G1-to-S phase transition (Figure 4) . 60 Furthermore, in the MCF-7 breast cancer cell line, treatment with 1␣,25(OH) 2 D 3 inhibits cellular proliferation, and microarray analysis demonstrated an up-regulation of a number of cell cycle regulatory genes, including p21-activated kinase 1 and p53. 61 Thus, vitamin D is a potent regulator of cellular differentiation and proliferation through direct regulation of cell cycle proteins. 2 2 D 3 is associated with growth factor signaling through transforming growth factor-␤ (TGF-␤), which is a potent inhibitor of proliferation of many cell types and is involved in cell cycle control and apoptosis. Vitamin D analogs induce an autocrine TGF-␤ activity through increasing expression of TGF-␤ isoforms or TGF-␤ receptors in nonmalignant and malignant cells. 64 Insulin-like growth factor (IGF)-binding protein 3 induction by 1␣,25(OH) 2 D 3 seems to contribute to its antiproliferative and proapoptotic actions in primary cancer cells. [65] [66] [67] Recent microarray studies of gene expression profiles in cancer cells have further highlighted the capacity of 1␣,25(OH) 2 D 3 analogs to drive malignant cells to a more differentiated state. 
Role of 1␣,25(OH)
70
In cultured malignant cells, 1␣,25(OH) 2 D 3 and its analogs down-regulate cellinvasion-associated proteases, including matrix metalloproteinases 2 and 9 and serine proteinases. 71 In prostate and colon cells, 1␣,25(OH) 2 D 3 and its analogs increase the expression of E-cadherin, a tumor suppressor associated with the metastatic potential of cells, and inhibit the oncogenic ␤-catenin signaling.
72 1␣,25(OH) 2 D 3 and its analogs inhibit the proliferation of some tumor-derived endothelial cells, inhibit the expression of vascular endothelial cell growth factor that induces angiogenesis in tumors, and suppress tenascin-C, which promotes growth, invasion, and angiogenesis during tumorigenesis. 73 Breast, colon, prostate, skin, lung, and a variety of other cell lines, when exposed to 1␣,25(OH) 2 D 3 , showed marked inhibition of cellular growth and induction of terminal differentiation. 74 Although vitamin D is not currently used as a chemotherapeutic agent, it shows promise for drug development in the treatment of certain cancers. However, at this point, it is far from a certainty.
Vitamin D Analogs for Cancer Treatment
As discussed earlier, the nuclear VDR has been isolated from a variety of target cells and tissues ( (Table 4) . Studies using the human osteosarcoma cell line MG-63 demonstrated that 3 of these analogs (KH1060, EB1089, and CB1093), have a greater antiproliferative effect than 1,25(OH) 2 D 3 . Treatment with these analogs increases p27 protein levels by increasing expression and decreasing degradation. The analogs cause decreased levels of cyclin E, decreased CDK2 kinase activity and hypophosphorylation of Rb, and inhibition of the G1-to-S phase transition. 105 Similar results have been seen in neuroblastoma cell lines treated with a 20-epi-1␣,25(OH) 2 D 3 analog, 106 suggesting that in the future, these 1␣,25(OH) 2 D 3 analogs may be useful in chemotherapeutic regimens.
Several other analogs are currently being tested in preclinical and clinical trials for the treatment of various types of cancer and osteoporosis, as well as immunosuppression. 80 Vitamin D analogs are effective treatments and are widely used as drugs for hyperproliferative skin disorders such as psoriasis, and in suppression of secondary hyperparathyroidism and parathyroid hyperplasia resulting from chronic renal insufficiency. [107] [108] [109] For instance, Gemini analogs have been recently found to be 100 -1000 times more potent in their antiproliferative activity than the natural hormone. Studies in mice suggest that they may be useful in the treatment of some cancers, including colon cancer. 27 Understanding how analogs exert their selective actions may allow for the design of more effective and safer vitamin D compounds for the treatment of a wide range of clinical disorders. The promising vitamin D analogs under development for the treatment of cancer are shown in Table 4 76 -88 ; the in vivo effects of vitamin D analogs in animal models for breast cancer, prostate cancer, and colon cancer are shown in Table 5 89 -106
; and the molecular targets 
Vitamin D and the Immune System
T Cells as the Main Target 1,25(OH) 2 D 3 seems to modulate immunity principally via regulating T-cell function. VDR has been found to be expressed on virtually every type of cell involved in immunity (Table 3) . 110 -113 The immunomodulatory actions of vitamin D are elicited through its direct action on T-cell and antigen-presenting cell (APC) functions. Thus, 1,25(OH) 2 D 3 may have an important physiologic role in immunoregulation and therapeutic target in immune-mediated diseases.
Effects on T Cells and T Helper 1 Cytokine Profiles: Relevance to Autoimmunity
In autoimmune patients, T cells target tissues such as the central nervous system (multiple sclerosis [MS] ), the gut (Crohn's disease, inflammatory bowel diseases [IBD]), the joints (rheumatoid arthritis) and the pancreas (type-1 diabetes). The common denominator between these diseases is that T-helper 1 (Th1) cells secrete a proinflammatory profile of cytokines (TNF-␣, interferon [INF] , IFN␥) at the site of pathology, which drives the disease process. In general, if a treatment for Th1-mediated autoimmunity works, it suppresses the number or activity of Th1 cells or antagonizes the cytokines (TNF-␣ in particular) that they produce. In addition, treatments that work for one Th1-driven disease are likely to suppress other Th1-driven autoimmune diseases (eg, infliximab used to treat Crohn's disease and rheumatoid arthritis). 124 VDRs are required to maintain a physiologic balance of Th1 and Th2 cell responses, and furthermore in the absence of the VDR, Th2 cell functions are diminished. 125 1␣,25(OH) 2 D 3 suppresses production of the Th1 proinflammatory cytokines interleukin-2 (IL-2) by binding to the distal nuclear factor of activated T cells (NF-AT) binding site in the promoter of the human IL-2 gene and IFN␥ through the interaction of VDRs, with a vitamin D response element (VDRE) in the promoter region of the IFN␥ gene. 126, 127 Because vitamin D deficiency favors a proinflammatory Th1 immune response, does supplementation rebalance immunity? In vitro addition of 1␣,25(OH) 2 D 3 has recently been shown to enhance and promote differentiation of type 2 T-helper (Th2) lymphocytes through a direct effect on naïve CD4 ϩ T cells. 1␣,25(OH) 2 D 3 has been shown in vitro to inhibit the development of Th1 cells while promoting the development of Th2 cells. 121, 128, 129 Thus, 1␣,25(OH) 2 D 3 seems to modulate T-cell differentiation, driving cells toward the Th2 phenotype and inhibiting Th1 development.
Thus, the action of 1␣,25(OH) 2 D 3 in antagonizing Th1 cytokine production while promoting Th2 function may have an important therapeutic role in diseases whereby Th1 cytokine responses drive the immunopathology.
Effects on APCs
The secretion of cytokines by APCs such as macrophages and dendritic cells (DCs) is crucial for the recruitment and activation of T lymphocytes. The actions of APCs on T cells are also influenced by 1␣,25(OH) 2 D 3 . Interleukin-12 (IL-12) is the principal APC-derived cytokine that determines the direction (Th1 vs Th2) of the immune response. Thus, Th1-stimulating cytokines are inhibited by 1␣,25(OH) 2 D 3 in DCs, as well as in other APCs. 124 
IL-12 stimulates the development of CD4
ϩ Th1 lymphocytes and inhibits the development of CD4 ϩ
Th2
lymphocytes. By inhibiting IL-12, 1␣,25(OH) 2 D 3 shifts the immune response away from a Th1 and toward a Th2 profile. Finally, 1␣,25(OH) 2 D 3 stimulates DC production of the immunosuppressive cytokine IL-10, which antagonizes the Th1 driving effects of IL-12. 130 These observations provide a rationale for use of vitamin D and its analogs in the prevention and treatment of autoimmune disease. 
Autoimmune Disease
Autoimmune diseases occur because of an inappropriate immune-mediated attack against self-tissue, resulting in tissue injury and disease. Both environmental and genetic factors play a vital role in disease development. Vitamin D availability via sun exposure or diet may contribute to the development of both MS and IBD. In support of this view, vitamin D and signaling through the VDR have been shown in mice to dictate the outcome of experimental MS and IBD. Vitamin D seems to regulate T-cell development and function, which may influence the outcome of the immune response either toward or away from autoimmunity. 131, 132 For example, in the absence of vitamin D and signals delivered through the VDR, autoreactive T cells develop, whereas in the presence of active 1␣,25(OH) 2 D 3 and a functional VDR, the balance in the T-cell response is restored and autoimmunity avoided. 133 Vitamin D from sunlight exposure is lower in areas where IBD occurs most often, as IBD is most prevalent in northern climates such as North America and Northern Europe. 134, 135 Vitamin D deficiency is common in patients with IBD even when the disease is in remission. 136, 137 Why vitamin D deficiency occurs more frequently in IBD is unclear. It is probably due to the combined effects of low vitamin D intake, malabsorption of many nutrients including vitamin D, and decreased outdoor activities in climates that are not optimal for vitamin D synthesis in the skin.
The strongest evidence that the VDR and its ligand have important roles in the pathogenesis of IBD comes from studies in mouse models. IL-10 knockout mice, model for the Crohn's disease form of IBD, spontaneously develop enterocolitis within 5-8 weeks of birth due to an uncontrolled immune response to resident intestinal flora in conventional animal facilities. 138 Approximately 30% of mice die subsequent to the development of severe anemia and weight loss. By contrast, IL-10 knockout mice raised in pathogen-free facilities develop a milder form of enterocolitis that does not result in death. Experimental IBD is induced by TNF-␣-and IFN␥-secreting Th1 cells. Th2 or T regulatory cells inhibit both the development and function (cytokine secretion) of Th1 cells. Cantorna 123 was the first to establish an experimental link between vitamin D status and IBD. The author showed that vitamin D deficiency exacerbates the symptoms of enterocolitis and increases morbidity and mortality in IL-10 knockout mice, whereas supplementation with vitamin D ameliorates IBD symptoms, reduces inflammation, and improves histologic scores and mortality. 123 They noted that 100% of the vitamin D-deficient IL-10 KO mice expressed symptoms of IBD (diarrhea, rectal bleeding) and 60% died before 9 weeks of age from complications of severe IBD. In contrast, vitamin D-sufficient mice showed no outward symptoms of IBD at the same time point. 134 Supporting the vitamin D deficiency data, mice that are both IL-10 and VDR deficient (double VDR/IL-10 KO) develop a fulminating form of experimental IBD that leads to 100% mortality by 7 weeks of age. 123 Interestingly, the severity of IBD in the VDR/IL-10 knockout mice is the same regardless of whether or not disease-causing microorganisms are present in the colony. Both vitamin D deficiency and VDR deficiency render experimental IBD more severe. These observations provide strong evidence that establishes vitamin D and VDR as a physiologic regulator of intestinal inflammation in IBD. The accumulating evidence for the immunomodulatory effects of VDR ligands certainly provides a rationale for further investigation of their potential in the treatment of IBD. A schematic depicting the potential role of vitamin D in Crohn's disease is shown in Figure 5 .
A large epidemiologic study showed an inverse relationship between vitamin D status and the development of MS. The study showed that women with the highest vitamin D intakes (including supplements) had a 40% reduction in the risk of developing disease. 139 Like IBD, vitamin D deficiency is common in patients with MS. 122 The cause of low 146 In this model of autoimmune diabetes, up-regulation of regulatory immune cells and a shift from Th1 toward Th2 lymphocytes locally in the pancreases of treated mice can be observed. This protective Th2 population is induced not only at the site of the ␤ cell attack but also in the peripheral immune system. 147 After immunization of 1␣,25(OH) 2 D 3 -treated NOD mice with a diabetes-specific autoantigen (a peptide of GAD65), lymphocytes of the draining lymph nodes showed an increased IL-4 and decreased IFN␥ production in vitro and in vivo. Strikingly, this immune deviation induced by 1␣,25(OH) 2 D 3 is limited to pancreatic autoantigens and could not be seen after immunization with the ␤ cell-irrelevant protein ovalbumin.
Other effects on the immune system of NOD mice have been described, the most important being a restoration of the defective apoptosis sensitivity of lymphocytes, leading to a more efficient elimination of potentially dangerous autoimmune effector cells. 148 This increased apoptosis induced by 1␣,25(OH) 2 D 3 and its analogs in DCs and T lymphocytes of NOD mice has been described after treatment with different apoptosis-inducing signals, such as corticosteroids, and could help to explain why an early short-term treatment with these agents, before onset of autoimmunity, confers long-term protection and promotes tolerance restoration.
Besides preventing the onset of autoimmune diseases, 1␣,25(OH) 2 D 3 and its analogs are also able to treat ongoing autoimmune diseases. Treatment of NOD mice with analogs of 1␣,25(OH) 2 D 3 can prevent the progression of an initial ␤ cell attack (reflected by the presence of insulitis) to clinical overt diabetes. 149 Interestingly, in this model of ongoing autoimmune destruction, no induction of suppressor cells by 1␣,25(OH) 2 2 D 3 are able to inhibit the recurrence of autoimmune diabetes after syngeneic islet transplantation in NOD mice. 150, 151 Development of noncalcemic vitamin D analogs could permit sustained systemic administration without causing significant hypercalcemia, thus allowing wider clinical applications in the future. Vitamin D supplementation, which is an inexpensive and efficient way to prevent vitamin D deficiency, might also help reduce the risk of autoimmune disease.
VDR Polymorphisms and Disease
Most of the biologic activities of 1␣,25(OH) 2 D 3 are mediated by a high-affinity receptor that acts as a ligand-activated transcription factor. The major steps involved in the control of gene transcription by the VDR include ligand binding, heterodimerization with retinoid X receptor (RXR), binding of the heterodimer to VDREs, and recruitment of other nuclear proteins into the transcriptional preinitiation complex. Thus, genetic alterations of the VDR gene could lead to important defects on gene activation, affecting calcium metabolism, cell proliferation, and immune function. For example, VDR gene mutations cause vitamin D-resistant rickets, a rare monogenetic disease. 152 A polymorphism is a genetic variant that appears in at least 1% of the population. These changes can occur in noncoding parts of the gene (introns), so they would not be seen in the protein product. Changes in these regulatory parts of the gene would then affect the degree of expression of the gene and thus the levels of the protein.
The discovery of genetic variants linked with susceptibility of diseases can be the key to advances in preventive medicine. In general, association studies can be used to test whether a polymorphism occurs more frequently in the cases studied than in the controls. If a relationship with the disease emerges from association studies, this finding would strongly support the idea that the candidate gene is in some way involved in the disease. The diseases associated with VDR polymorphisms are summarized in Table 7 . 153 Carling et al 154 reported a relationship between the BsmI polymorphism and primary hyperparathyroidism. Recently, 2 meta-analyses performed by Thakkinstian et al 155, 156 demonstrated a positive association between the b allele and bone mass density. Furthermore, it was shown that the haplotypes Bat and BAt were significantly associated with osteoporosis.
An association has been described between VDR polymorphisms and susceptibility to and outcome of some cancers, like breast, prostate, and colon cancers. In 1997, Ingles et al 157 158 showed the relationship between the TaqI polymorphism and an increased risk of prostate cancer, whereas the restriction site (tt) was associated with a lower risk with higher levels of 1␣,25(OH) 2 D 3 . 159 However, other investigators found no association between TaqI or polyA and prostate cancer. 160 -162 In the case of other VDR polymorphisms (FokI, BsmI), conflicting results can be found as well. 159, [162] [163] [164] [165] In addition, a recent meta-analysis of 28 different studies was performed, and no relationship was found between any of the former VDR polymorphisms and prostate cancer susceptibility. 166 As with prostate cancer, conflicting results have been reported regarding the possible relationship between breast cancer and VDR polymorphisms. The majority of the reports present in the literature found no relationship between the risk of breast cancer and TaqI polymorphism, but some of them presented a link between TaqI polymorphism and risk of metastases. [167] [168] [169] [170] [171] The BsmI shows an opposite pattern, with a relationship detected in 3 reports. [172] [173] [174] In the case of FokI the consensus is higher, and most of the reports showed no association with increased risk of breast cancer. 171, 173, 174 To date, studies investigating the relationship between polyA or ApaI 170, 171 and the risk of breast cancer showed a link between these VDR polymorphisms and the possibility of presenting a tumor. The number of papers analyzing VDR polymorphisms in other cancer types is significantly lower. Regarding colon carcinoma, there are reports showing an association with BsmI polymorphism, 175, 176 whereas conflicting results are found regarding FokI. 177, 178 VDR polymorphisms have been described in a number of autoimmune diseases. A positive relationship between the B allele of the BsmI polymorphism and a lack of a relationship between the FokI polymorphism and the incidence of systemic lupus erythematosus has been observed. 179 -181 In the case of Crohn's disease, a link has been suggested between the TaqI, ApaI and FokI polymorphisms and disease susceptibility. 182 Furthermore, a link between BsmI and FokI with primary biliary cirrhosis and autoimmune hepatitis has also been found. 183, 184 In MS patients, a higher presence of the bA haplotype has been detected, 185, 186 whereas TaqI 187 and FokI 188 polymorphisms were observed. In summary, a vast amount of information has been collected through the years regarding the association of vitamin D polymorphisms with susceptibility to contract different diseases. Unfortunately, the results obtained so far are conflicting, and the role of VDR polymorphisms remains obscure. Therefore, the use of VDR polymorphisms as diagnostic tools, or even as markers for a higher propensity toward some diseases, is still a matter of debate.
Recommendations and Conclusion
Vitamin D deficiency is a common clinical problem in the United States. 189 -194 Because most patients with mild deficiency are asymptomatic, physicians should have a high index of suspicion in populations at highest risk for deficiency. Identification and treatment of patients with vitamin D deficiency are important for optimal bone development and muscle strength. The major source of vitamin D for both children and adults comes from reasonable sun exposure. In the absence of sun exposure, most experts now agree that 1000 IU of vitamin D is needed daily in the absence of sun exposure to maintain a healthy blood level of 25(OH)D of between 75 and 125 nmol/L (30 -50 ng/mL). 194 -200 However, vitamin D supplementation is not widely practiced and most supplements only contain 400 IU of vitamin D. As reviewed in this manuscript, in addition to bone health, there is mounting scientific evidence that implicates vitamin D deficiency with an increased risk of autoimmune disease and many common deadly cancers. Children over the age of 1 year and all adults should receive 1000 IU of vitamin D per day, or have judicious sun exposure to satisfy their vitamin D requirement. Measurement of 25(OH)D should be encouraged. The risks and potential benefits of vitamin D supplementation should be further studied for use in patients who either have or are at high risk for breast, colon, and prostate cancer and autoimmune diseases. 
